trending Market Intelligence /marketintelligence/en/news-insights/trending/hTu93_vGDNaydZq8Aa6nXg2 content esgSubNav
In This List

Taiyen Biotech Q3 profit falls YOY


Expand Your Perspective: Intelligence


Next in Tech | Episode 66: Connected vehicles in transition


Gold - Geopolitical tensions and inflation remain key drivers


Lithium and Cobalt - Softer demand weighs on prices

Taiyen Biotech Q3 profit falls YOY

Taiyen Biotech Co. Ltd. said its normalized net income for the third quarter amounted to 38 Taiwan cents per share, a decrease of 8.1% from 41 cents per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$75.3 million, a decline of 8.1% from NT$82.0 million in the prior-year period.

The normalized profit margin dropped to 9.6% from 11.2% in the year-earlier period.

Total revenue grew year over year to NT$739.1 million from NT$729.1 million, and total operating expenses decreased on an annual basis to NT$608.2 million from NT$638.2 million.

Reported net income decreased 16.7% on an annual basis to NT$100.1 million, or 50 cents per share, from NT$120.1 million, or 60 cents per share.

As of Nov. 9, US$1 was equivalent to NT$31.55.